JP2024512982A5 - - Google Patents

Info

Publication number
JP2024512982A5
JP2024512982A5 JP2023559727A JP2023559727A JP2024512982A5 JP 2024512982 A5 JP2024512982 A5 JP 2024512982A5 JP 2023559727 A JP2023559727 A JP 2023559727A JP 2023559727 A JP2023559727 A JP 2023559727A JP 2024512982 A5 JP2024512982 A5 JP 2024512982A5
Authority
JP
Japan
Prior art keywords
seq
sequence
heavy chain
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023559727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512982A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023058 external-priority patent/WO2022212848A1/en
Publication of JP2024512982A publication Critical patent/JP2024512982A/ja
Publication of JP2024512982A5 publication Critical patent/JP2024512982A5/ja
Pending legal-status Critical Current

Links

JP2023559727A 2021-04-02 2022-04-01 アゴニスト抗il-2r抗体及び使用方法 Pending JP2024512982A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163170383P 2021-04-02 2021-04-02
US63/170,383 2021-04-02
US202163239883P 2021-09-01 2021-09-01
US63/239,883 2021-09-01
PCT/US2022/023058 WO2022212848A1 (en) 2021-04-02 2022-04-01 Agonistic anti-il-2r antibodies and methods of use

Publications (2)

Publication Number Publication Date
JP2024512982A JP2024512982A (ja) 2024-03-21
JP2024512982A5 true JP2024512982A5 (cg-RX-API-DMAC7.html) 2025-04-07

Family

ID=81385128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023559727A Pending JP2024512982A (ja) 2021-04-02 2022-04-01 アゴニスト抗il-2r抗体及び使用方法

Country Status (18)

Country Link
US (3) US11884735B2 (cg-RX-API-DMAC7.html)
EP (1) EP4314067A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024512982A (cg-RX-API-DMAC7.html)
KR (1) KR20230165263A (cg-RX-API-DMAC7.html)
AU (1) AU2022252398A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020219A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214587A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023002895A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023014054A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230507A (cg-RX-API-DMAC7.html)
IL (1) IL305944A (cg-RX-API-DMAC7.html)
JO (1) JOP20230234A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011624A (cg-RX-API-DMAC7.html)
PE (1) PE20240913A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023552763A1 (cg-RX-API-DMAC7.html)
TW (1) TW202304994A (cg-RX-API-DMAC7.html)
UY (1) UY39715A (cg-RX-API-DMAC7.html)
WO (1) WO2022212848A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
TW202304994A (zh) * 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗il-2r抗體及使用方法
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
TW202602940A (zh) 2024-04-09 2026-01-16 美商安進公司 激動性抗il-2rbg重鏈抗體
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2026033139A1 (en) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトIL−2レセプターγ鎖分子
WO1996021732A1 (en) 1995-01-09 1996-07-18 Boehringer Ingelheim International Gmbh Il-2r-associated polypeptide and dna molecules coding therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU2937597A (en) 1996-05-10 1997-12-05 Biogen, Inc. Common gamma chain blocking agents
US6103879A (en) 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
JP2006505546A (ja) 2002-10-10 2006-02-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 二重特異性抗ErbB抗体および腫瘍治療でのその使用
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
PT3328894T (pt) * 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
CN111954680B (zh) 2017-11-10 2024-03-15 新加坡科技研究局 IL2Rβ/共同γ链抗体
WO2020094836A1 (en) * 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
WO2020094834A1 (en) * 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
CN113474370B (zh) 2019-02-01 2025-04-01 瑞泽恩制药公司 抗IL2受体γ抗原结合蛋白
TW202304994A (zh) * 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗il-2r抗體及使用方法

Similar Documents

Publication Publication Date Title
Zhang et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma
US12054557B2 (en) Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer
AU2020276242B2 (en) Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
JP2023025202A5 (cg-RX-API-DMAC7.html)
JP2019536430A5 (cg-RX-API-DMAC7.html)
RU2019138067A (ru) Биспецифическое антитело против ox40 и ctla-4
WO2022187539A1 (en) Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
JP2022537780A5 (cg-RX-API-DMAC7.html)
JP2020500181A5 (cg-RX-API-DMAC7.html)
AU2016378573A1 (en) Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia
JP2018502050A5 (cg-RX-API-DMAC7.html)
JP2017500018A5 (cg-RX-API-DMAC7.html)
JP2019505527A5 (cg-RX-API-DMAC7.html)
JP2011514150A5 (cg-RX-API-DMAC7.html)
JP2022538083A5 (cg-RX-API-DMAC7.html)
JP2018515532A5 (cg-RX-API-DMAC7.html)
RU2018107693A (ru) Комбинированные виды лечения и их варианты применения и способы
JP2022538089A5 (cg-RX-API-DMAC7.html)
JP2024510811A5 (cg-RX-API-DMAC7.html)
JP2021520393A5 (cg-RX-API-DMAC7.html)
JP2021525806A5 (cg-RX-API-DMAC7.html)
JP2017515473A5 (cg-RX-API-DMAC7.html)
JP2022506761A5 (cg-RX-API-DMAC7.html)
JP2020517671A5 (cg-RX-API-DMAC7.html)
JPWO2022114163A5 (cg-RX-API-DMAC7.html)